

Sanofi – Discontinuation of Adlyxin[®] (lixisenatide)

- On January 1, 2023, <u>Sanofi announced</u> that <u>Adlyxin (lixisenatide)</u> will no longer be available in the U.S. market.
 - The discontinuation was a business decision and was not due to safety or efficacy issues.
- Adlyxin is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Product Description	NDC#
Adlyxin (lixisenatide) 50 mcg/mL, 3 mL single- patient-use prefilled pen	0024-5741-01
Adlyxin (lixisenatide) 100 mcg/mL, 3 mL single-patient-use prefilled pen	0024-5740-00

Other injectable GLP-1 agonists indicated for the treatment of type 2 diabetes include <u>Trulicity®</u> (<u>dulaglutide</u>), <u>Byetta®</u> (<u>exenatide</u>), <u>Bydureon BCise®</u> (<u>exenatide</u> extended-release), <u>Victoza®</u> (<u>liraglutide</u>), <u>Mounjaro™</u> (<u>tirzepatide</u>), and <u>Ozempic®</u> (<u>semaglutide</u>). <u>Soliqua® 100/33 (insulin glargine and lixisenatide</u>) will continue to be available.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.